Short Duration High Intensity Intrapleural Alteplase With Pulmozyme in Pleural Infection Management (NCT04915586) | Clinical Trial Compass
CompletedNot Applicable
Short Duration High Intensity Intrapleural Alteplase With Pulmozyme in Pleural Infection Management
Malaysia30 participantsStarted 2019-12-30
Plain-language summary
The aim of this study was to assess the efficacy of the modified regimen short duration intrapleural 16mg alteplase (Actilyse, Boehringer Ingelheim) with 5mg DNase (Pulmozyme Hoffmann-La Roche Ltd) in patients with pleural infection.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* adult patient with age more than 17 year old
* evidence of complex parapneumonic effusion or empyema; with poor pleural fluid drainage of ≤150 mL after 24 hours of insertion of chest drain
* clinical evidence of infection such as fever and or elevated C-reactive protein (CRP) or white-cell count
* complex pleural effusion proven by ultrasound
* pleural fluid analysis that fulfilled at least one of the characteristics: frank pus, exudative nature (according to light's criteria), gram stain or culture positive, lactate dehydrogenase (LDH) \> 1000 U/L, pH \< 7.2 and/or glucose level \< 3.3mmol/L
Exclusion Criteria:
* known allergy to pulmozyme or alteplase
* acute stroke, active bleeding diathesis
* major surgery in past 5 days
* previous pneumonectomy on the infected side
* bronchopleural fistula
* pregnancy
* coagulopathy (INR \> 2, APTT \>100, platelet count \< 50,000 cells)
What they're measuring
1
Radiographic improvement in pleural opacity on chest radiograph